Overview
- Dexcom reported second-quarter results on July 30 with $1.31 billion in revenue and $249.1 million in net profit, topping Wall Street forecasts.
- The company raised the midpoint of its 2026 revenue outlook to a $5.18 billion–$5.25 billion range and nudged up its margin targets for the year.
- Executives pointed to CONNECT trial results showing an average 1.6% A1C drop at 26 weeks versus self‑monitoring, the FDA’s pediatric OTC clearance for Stelo, and an active G7 rollout as key commercial and clinical drivers.
- Investors reacted to the beat and guidance change with shares jumping more than 8% at market open and the company’s market value near $29 billion.
- Management highlighted expanding reimbursement in markets such as France and Canada, the Nutrisense acquisition and long‑term goals to sustain >10% organic growth and higher margins through 2030 as the strategic backdrop for continued adoption.